论文部分内容阅读
摘要目的评估高危恶性肾肿瘤病人在接受经皮影像引导下射频消融治疗后生存者的长期随访结果。方法回顾分析2002—2009年62例病人(71个肿瘤),中位年龄73.5岁(20~87岁),均因为肾恶性肿瘤而连续接受超声或CT引导下的射频消融治疗,并对其进行预后随访直至2012年。62例病人中包括25例(40.3%)独肾病人及7例囊性肾癌,最大肿瘤直径在8~46 mm间(中位数为23 mm)。结果射频消融在技术方面对于所有病人是可行的,平均随访时长为38.8个月(18~78个月)。每例病人各自的主要和次要的技术效益
Abstract Objective To evaluate the long-term follow-up of survivors of radiofrequency ablation-guided radiofrequency imaging in patients with high-risk malignant renal tumors. Methods A retrospective analysis of 62 patients (71 tumors) from 2002 to 2009, with a median age of 73.5 years (range, 20-87 years), was performed consecutively under ultrasound or CT-guided radiofrequency ablation due to renal malignancy and was performed Prognosis followed up until 2012. Sixty-two patients (25.3%) had renal disease and 7 had cystic renal cell carcinoma with a maximum tumor diameter of 8 to 46 mm (median, 23 mm). Results Radiofrequency ablation was technically feasible for all patients with an average follow-up of 38.8 months (18-78 months). Each patient’s respective major and minor technical benefits